Clinical trials located in

Namur

Namur city is located in Belgium. Currently, 20 clinical trials are being conducted in this city.

Namur, the capital of Wallonia, Belgium, is nestled at the confluence of the Meuse and Sambre rivers. This charming city is renowned for its strategic importance throughout history, evidenced by the imposing Citadel that has been a military fortification since Roman times. Namur is also celebrated for its vibrant cultural scene, hosting the annual International Francophone Film Festival. The city’s rich history is complemented by its picturesque medieval architecture, including the Saint Aubain Cathedral, a masterpiece of Baroque architecture.

  • CT-EU-00121743

    Study comparing Giredestrant and Fulvestrant with CDK4/6 Inhibitors for advanced breast cancer

    This study focuses on a type of advanced breast cancer known as Estrogen Receptor-Positive (ER+), HER2-Negative breast cancer. This kind of cancer is driven by hormones and does not have high levels of the HER2 protein. The study aims to evaluate the effectiveness and safety of a new drug called Giredestrant compared to an existing drug called Fulvestrant. Both drugs will be combined with one of three medicines that inhibit proteins in cancer cells called CDK4/6 inhibitors (Palbociclib, Ribociclib, or Abemaciclib).

    In this study, participants will be randomly assigned to one of two groups. One group will receive Giredestrant and the other will receive Fulvestrant. Both groups will also receive one of the CDK4/6 inhibitors chosen by their doctor. These combinations are being tested to see which works better to stop the cancer from growing or spreading.

    The drugs involved include Giredestrant (RO7197597, RG6171, GDC-9545), Fulvestrant, Abemaciclib, Palbociclib, Ribociclib, and LHRH Agonist (for pre/perimenopausal women and men).

    The goal is to find out if Giredestrant can provide better results and fewer side effects compared to Fulvestrant when both are combined with one of the CDK4/6 inhibitors. The study may involve regular tests and assessments to monitor the cancer’s progress and the patient’s response to the treatment.

    Participants will continue to receive the study drugs as long as they are benefiting from them and not experiencing unacceptable side effects. The study involves close monitoring to ensure the safety and well-being of all participants throughout the treatment period.

    • LHRH Agonist
    • Abemaciclib
    • Giredestrant
    • Palbociclib
    • Ribociclib
    • Fulvestrant
  • CT-EU-00068410

    A study of the treatment of advanced breast cancer with Giredestrant and the drug combination Phesgo

    The study is aimed at patients with locally advanced or metastatic breast cancer that is HER2-positive and ER-positive. HER2 and ER are receptors that can influence the growth of cancer cells. The aim of this study is to evaluate the effectiveness and safety of the combination of giredestrant and Phesgo compared with Phesgo alone after a run-in phase with Phaesgo and taxane-based chemotherapy.

    Phesgo is a combination containing pertuzumab, trastuzumab and hyaluronidase, administered subcutaneously every three weeks. Giredestrant is a capsule taken orally every day. Taxane chemotherapy may include drugs such as Docetaxel and Paclitaxel, which are given intravenously. The aim of the study is to compare how well these drug combinations work in preventing disease progression and improving patient survival.

    • hyaluronidase
    • Giredestrant
    • Pertuzumab
    • Trastuzumab
    • Paclitaxel
    • Docetaxel
  • CT-EU-00068643

    Study of the effects and safety of Inavolisib and Fulvestrant compared with Alpelisib and Fulvestrant in patients with advanced breast cancer

    The clinical trial is for breast cancer. Its aim is to evaluate the effectiveness and safety of the drug combination inavolisib and fulvestrant compared with the drug combination alpelisib and fulvestrant.

    It is aimed at patients with locally advanced or metastatic breast cancer. All patients who will participate in the study have previously undergone therapy based on cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitors and hormonal therapy. Study participants’ breast cancer must be hormone receptor positive (HR+), human epidermal growth factor receptor type 2 negative (HER2-), and must have a PIK3CA gene mutation.

    The aim of the study is to compare which drug combination – inavolisib and fulvestrant or alpelisib and fulvestrant – is more effective in the treatment of this type of breast cancer. This study also tries to assess what the side effects of both therapies are.

    Inavolisib and fulvestrant treatment involves administering inavolisib tablets once a day and fulvestrant injections at the beginning and during treatment cycles. An alternative treatment, i.e. alpelisib with fulvestrant, also involves daily use of alpelisib tablets and fulvestrant injections according to planned cycles.

    • Alpelisib
    • Fulvestrant
    • Inavolisib
  • Study on combining two drugs – Fianlimab and Cemiplimab in patients with previously untreated melanoma

    This study examines two drugs, fianlimab and cemiplimab, given together for the treatment of melanoma. The main goal is to see how effective this drug combination is in treating melanoma compared with pembrolizumab, which is already approved for the treatment of melanoma in adults. The study will also look at whether there are any differences in the effects of these experimental drugs in adolescents and adults.

    Scientists also want to learn about other key issues: what side effects may occur from taking these experimental drugs, how much of the drugs enter the bloodstream over time, and whether the body produces antibodies to the drugs that could make them less effective or cause side effects. They will also check whether taking medications improves patients’ quality of life. Fianlimab and cemiplimab will be administered by intravenous infusion, and pembrolizumab will be administered by intravenous infusion.

    • placebo
    • Fianlimab
    • Cemiplimab
    • Pembrolizumab
  • Testing tozorakimab’s effect on chronic lung disease symptoms

    This study is all about testing a new drug, Tozorakimab, for people who have COPD – a lung disease that makes it difficult to breathe—and have had a bad flare-up in the past year. The researchers will give some people the new drug and some people a placebo (a dummy treatment) and see which works best. The drug is delivered in a shot under the skin, and all the people in the study will also keep taking their usual COPD medicines. The main things the researchers will be looking at are whether the new drug can reduce the number of flare-ups, improve quality of life (measured using a questionnaire), reduce the need for rescue medication and if it changes the results of breathing tests.

    • Tozorakimab
  • Study of treatment effects in patients with narcolepsy switching from sodium oxybate to a new drug – JZP258

    This clinical trial is focused on narcolepsy, a sleep disorder that causes excessive daytime sleepiness and sudden sleep attacks. The study will evaluate a treatment transition from high-sodium oxybate, like XYREM, to a low-sodium oxybate called XYWAV (also known by its code name, JZP258). JZP258 contains a combination of calcium, magnesium, potassium, and sodium oxybates.

    The main purpose of this study is to measure changes in blood pressure when participants switch from high-sodium oxybate to JZP258. Understanding these changes could help doctors and patients make better-informed decisions about narcolepsy treatments with different sodium contents.

    During the trial, participants will receive a dose of JZP258 ranging from 6 to 9 grams per night over a period of 6 weeks. The study is open-label, which means both the researchers and participants will know they are receiving JZP258.

    The trial seeks to enroll about 89 participants who currently use high-sodium oxybate for narcolepsy treatment. These participants will switch to JZP258 to see how it affects their blood pressure.

    • JZP258/XYWAV
  • Testing safety and effects of telisotuzumab and docetaxel in Lung Cancer patients

    This study is for adults who have been treated before for a type of lung cancer called non-small cell lung cancer (NSCLC). The aim is to see if a new drug, called telisotuzumab vedotin, works better and is as safe as a common drug called docetaxel. In this study, cancer activity and any side-effects will be observed closely. The treatment will be given by a drip into a vein.The researchers will randomly decide whether each participant will get telisotuzumab vedotin or docetaxel, with an equal chance of getting either drug. While in the study, each person will have regular hospital or clinic visits to check how they are doing with tests and questionnaires.

    • Telisotuzumab Vedotin
    • Docetaxel
  • Testing zimberelimab and domvanalimab with chemotheraphy for lung cancer

    This clinical trial explores the effectiveness of two new medicines, zimberelimab and domvanalimab, in tandem with chemotherapy for patients with untreated metastatic non-small cell lung cancer. The study’s main goal is to compare the impact and success of this combination treatment versus a control group receiving pembrolizumab along with chemotherapy. The hopeful outcome of the trial is to identify whether the new combination of drugs can provide enhanced benefits for the involved patients. Regular health monitoring will occur during the trial to ensure patient safety.

    • Pemetrexed
    • Nab-paclitaxel
    • Paclitaxel
    • Cisplatin
    • Carboplatin
    • Pembrolizumab
    • Domvanalimab
    • Zimberelimab
  • Study of Inavolisib for patients with advanced HER2-positive breast cancer with a PIK3CA mutation

    The study is aimed at people with advanced breast cancer, including those that have spread to other parts of the body (metastatic breast cancer). The treatment used in the study includes a combination of inavolisib and Phesgo, which is a combination of pertuzumab and trastuzumab administered subcutaneously. For comparison, some patients will also receive a placebo in combination with Phesgo.

    The aim of the study is to evaluate the effectiveness and safety of inavolisib in combination with Phesgo as maintenance therapy after first-line therapy in patients with PIK3CA mutation and HER2-positive advanced breast cancer. HER2-positive breast cancer is one in which there is an excess of HER2 receptors, which stimulates the growth of cancer cells. The PIK3CA mutation occurs in the genes of cancer cells, which can affect their growth and response to treatment.

    Many people in the study have not previously received treatment for advanced or metastatic breast cancer and, after completing initial therapy, will be randomized (randomization) to one of the study groups: maintenance therapy with inavolisib and Phesgo or placebo and Phesgo.

    The study also provides for the possibility of using additional hormonal therapy at the discretion of the attending physician. Hormone therapy, such as tamoxifen or aromatase inhibitor drugs (e.g. letrozole, anastrozole), is sometimes used to treat breast cancer to block the effect of hormones on its growth.

    • PHESGO
    • Inavolisib
  • Examining povorcitinib for treating hidradenitis suppurativa

    This study is about a drug called Povorcitinib, also known as INCB054707. It’s being tested on people who have moderate to severe Hidradenitis Suppurativa (HS), a painful skin condition. The trial will last for 12 weeks, and then there will be an extension period of 42 weeks. The aim of the trial is to see whether the drug is both safe, and effective enough to reduce the symptoms by at least 50%, without increasing certain symptoms like abscesses or tunnels formed by the disease. The study will also look at whether the drug significantly reduces skin pain and improves quality of life.

    • povorcitinib
  • Studying guanfacine treatment for ADHD

    This research focuses on investigating the medication Guanfacine hydrochloride (TAK-503) for individuals aged 6–17 years diagnosed with ADHD. The study is divided into two phases: initially comparing Guanfacine hydrochloride with another medication along with placebo. Subsequently, all participants will receive Guanfacine hydrochloride for an entire year. The primary objective is to determine whether Guanfacine hydrochloride can be beneficial for young individuals who have not responded to other ADHD treatments. Throughout the study, participants will engage in computer tests to assess cognitive functions such as processing speed, memory, and learning abilities. Changes in participants’ physical characteristics, such as height and weight, will be measured due to potential effects of the medication. Additionally, the study aims to understand if Guanfacine hydrochloride has an impact on the mood or sleepiness of the participants, and parents will provide relevant information by answering specific questions.

    • Guanfacine hydrochloride/TAK-503
    • Atomoxetine hydrochloride
  • Examining the impact of 2LHERP® on recurrent herpes

    This is a study to test a medication called 2LHERP for treating sores caused by a common virus named Herpes in the mouth and face area. 2LHERP will be compared with a placebo, which looks like 2LHERP but doesn’t have any medicine in it. 2LHERP has been available for over 20 years and has shown to be useful in treating these sores by controlling the body’s immune response. Now, in this trial, doctors want to study more on how effective it really is in treating these sores. The main goal is to see if 2LHERP can reduce the number of times these sores reappear over 12 months.

    • 2LHERP®
  • Study testing Ruxolitinib cream for Prurigo Nodularis treatment

    This study is testing a cream with Ruxolitinib to see if it’s safe and effective for people with a skin condition called Prurigo Nodularis (PN). The study has three main parts. In the first 12 weeks, participants will receive either the cream with Ruxolitinib or placebo (also known as vehicle-controlled) treatment. After that, all participants will receive the cream with Ruxolitinib for another 40 weeks. After that, there will be an extra 30 days to keep an eye on safety. The trial will measure success by checking if the cream can reduce itchiness. Treatment success will be evaluated by medical professionals, considering factors such as the number of skin nodules and the extent of redness and crusting in the condition’s severity.

    • Ruxolitinib
  • Study to test targeted therapy for invasive lobular breast cancer

    This research study is for people with Invasive Lobular Carcinoma of the Breast (ILBC). This type of cancer is mostly treated like another type called Invasive Ductal Breast Carcinoma (IDBC) even though ILBC has different characteristics. The study is exploring whether a certain drug might help treat it. This particular study will evaluate a drug known as Entrectinib combined with another drug called letrozole (and also goserelin for women who have not been through menopause). The treatment will take place before any surgery (called neoadjuvant therapy) and will last for 4 months. The goal is to see if these drugs can reduce the size of the cancer before surgery.

    • Entrectinib
    • goserelin
    • Letrozole
  • Testing ADT with or without darolutamide in prostate cancer patients

    This study is about testing how well two different kinds of prostate cancer treatment work. One treatment is called ADT (Androgen deprivation therapy) and the other is called darolutamide. In total, around 300 men who have just been diagnosed with prostate cancer will take part. The people in the study will be split into two groups. Half of the people will have the ADT treatment with placebo, while the other half will have both the ADT and darolutamide treatment. This will help the researchers understand whether adding darolutamide makes the ADT treatment work better. To check how well the treatment is working, the researchers will be using different methods.

    • Androgen deprivation therapy
    • Darolutamide
  • Exploring magrolimab use for head and neck tumors

    This is a study about treatment of patients with squamous cell carcinoma, a type of head and neck cancer. The study will test the safety and effectiveness of a drug called magrolimab, used together with other cancer treatments. The study wants to know how well the treatment works. Throughout the trial, participants’ health will be closely monitored. This includes regular medical check-ups, imaging tests, and other diagnostic procedures to assess how well the cancer is responding to the treatment regimen.

    • Magrolimab
    • Cisplatin
    • Carboplatin
    • Pembrolizumab
    • Zimberelimab
    • 5-Fluorouracil
    • Docetaxel
  • Testing a treatment for Human Papilloma Virus

    This experiment involves the use of a medication known as 2LPAPI to treat infections caused by HPV, a widespread virus. The primary objective of this study is to assess the effectiveness of 2LPAPI in treating HPV infections specifically located in the genital areas of women. The study spans a 4-year timeframe, during which doctors will closely monitor the infection to evaluate the medicine’s efficacy. The study protocol includes a main treatment period lasting for 6 months, during which the participants will receive the medication. Subsequently, doctors will continue to track the infection for an additional 6 months. The study is seeking women aged between 25 and 45 who exhibit irregularities in their cervix during regular check-ups.

    • 2LPAPI
  • Inupadenant study in second-line non-small cell lung cancer

    This clinical trial aims to explore the potential of inupadenant (EOS100850) when combined with standard chemotherapy drugs, carboplatin and pemetrexed, in treating advanced non-small cell lung cancer in adults. The study is particularly focused on patients for whom previous immunotherapy treatments were not successful.

    The trial has two primary goals. Initially, it seeks to determine the most effective and safest dose of inupadenant when used alongside chemotherapy. Once the optimal dosage is established, the next phase involves comparing the treatment’s effectiveness against a placebo, in combination with the chemotherapy drugs.

    Throughout the study, participants’ health and responses to the treatment are closely monitored.

    • inupadenant
    • Pemetrexed
    • Carboplatin
  • Comparison of different treatments for follicular lymphoma

    This study involves comparing two treatments for a condition known as follicular or marginal zone lymphoma, both of which are types of cancer affecting lymph cells. The first treatment combines zanubrutinib with an antibody called Anti-CD20, while the second treatment involves lenalidomide and rituximab. These treatments are intended for patients who have not responded or have stopped responding to conventional treatment. One of the primary objectives of the study is to determine which treatment is more effective in preventing the cancer from progressing, referred to as progression-free survival. Additionally, the study aims to assess the impact of these treatments on the patients’ quality of life, evaluating various aspects through questionnaires related to physical and emotional well-being, symptoms, and the ability to perform normal activities.

    • Zanubrutinib
    • Obinutuzumab
    • Lenalidomide
    • Rituximab
  • Study on dazostinag & pembrolizumab for advanced solid tumors

    The purpose of this study is to test a new drug called dazostinag. A study is being conducted to see whether this drug is helpful in adults with advanced forms of solid cancer. Some people are given dazostinag alone, while others are given it with another medicine called pembrolizumab. Scientists’ focus here is on finding out whether these drugs cause any side effects, and finding out what the maximum dose is that people can take without serious side effects. The study consists of two parts, including a dose escalation phase and a dose escalation phase. In the first part, the dose of dazostinag will be gradually increased, given alone or in combination with pembrolizumab. In the second part, Dazostinag will be tested with pembrolizumab and other anticancer drugs. This section will focus on patients with specific cancers that are difficult to remove or have spread to other parts of the body.

    • Dazostinag
    • Platinum
    • Pembrolizumab
    • 5-Fluorouracil

See more clinical trials in other cities in Belgium:

.